1. Diabetes. 2020 Jan;69(1):112-120. doi: 10.2337/db19-0097. Epub 2019 Oct 21.

Interaction Between Type 2 Diabetes Prevention Strategies and Genetic 
Determinants of Coronary Artery Disease on Cardiometabolic Risk Factors.

Merino J(1)(2)(3)(4)(5), Jablonski KA(6), Mercader JM(1)(2)(3), Kahn SE(7), Chen 
L(1)(2)(3), Harden M(8), Delahanty LM(2)(4), Araneta MRG(9), Walford GA(1)(2), 
Jacobs SBR(1)(2)(3), Ibebuogu UN(10), Franks PW(11)(12)(13), Knowler WC(14), 
Florez JC; Diabetes Prevention Program Research Group.

Collaborators: Bray GA, Gadde K, Chatellier A, Arceneaux J, Dragg A, Duncan C, 
Greenway FL, Hsia D, Levy E, Lockett M, Ryan DH, Ehrmann D, Matulik MJ, Czech K, 
DeSandre C, Goldstein BJ, Furlong K, Smith KA, Wildman W, Pepe C, Goldberg RB, 
Calles J, Ojito J, Castillo-Florez S, Florez HJ, Giannella A, Lara O, Veciana B, 
Haffner SM, Hazuda HP, Montez MG, Hattaway K, Lorenzo C, Martinez A, Walker T, 
Hamman RF, Dabelea D, Testaverde L, Anderson D, Bouffard A, Jenkins T, Lenz D, 
Perreault L, Price DW, Steinke SC, Horton ES, Poirier CS, Swift K, Caballero E, 
Fargnoli B, Guidi A, Guido M, Jackson SD, Lambert L, Lawton KE, Ledbury S, 
Sansoucy J, Spellman J, Kahn SE, Montgomery BK, Fujimoto W, Knopp RH, Lipkin EW, 
Morgan-Taggart I, Murillo A, Taylor L, Thomas A, Tsai EC, Trence D, Kitabchi AE, 
Dagogo-Jack S, Murphy ME, Taylor L, Dolgoff J, Clark D, Ibebuogu U, Lambeth H, 
Ricks H, Rutledge LMK, Soberman JE, Molitch ME, Metzger BE, Johnson MK, Giles 
MM, Larsen D, Pen SC, Nathan DM, Larkin M, McKitrick C, Turgeon H, Anderson E, 
Bissett L, Bondi K, Cagliero E, D'Anna K, Delahanty L, Florez JC, Goldman V, Lou 
P, Poulos A, Raymond E, Stevens C, Tseng B, Barrett-Connor E, Carrion-Petersen 
ML, Claravall LN, Dowden JM, Horne J, Leos D, Mudaliar S, Smith J, Janisch SS, 
Vejvoda K, Pi-Sunyer FX, Lee JE, Foo ST, Hagamen S, Marrero DG, Mather KJ, Kelly 
SM, Putenney P, Jackson MA, McAtee G, Ackermann RT, Cantrell CM, Fineberg ES, 
Hadden A, Kirkman MS, O'Kelly Phillips E, Roach PJ, Ratner RE, Aroda V, Shapiro 
S, Bavido-Arrage C, Gibbs P, Uwaifo G, Wiggins R, Saad MF, Watson K, Botrous M, 
Jinagouda S, Budget M, Conzues C, Magpuri P, Ngo K, Xapthalamous K, White NH, 
Brown AL, Das S, Khare-Ranade P, Stich T, Santiago A, Wernimont C, Saudek CD, 
Golden SH, Whittington T, Brancati FL, Clark JM, Greene A, Jiggetts D, Mosley H, 
Reusing J, Rubin RR, Stephens S, Utsey E, Schade DS, Adams KS, Hemphill C, Hyde 
P, Canady JL, Colleran K, Gonzales Y, Hernandez-McGinnis DA, King C, Crandall J, 
Brown JO, Trandafirescu G, Adorno E, Duffy H, Goldstein A, Lukin J, Martinez H, 
Pompi D, Shamoon H, Scheindlin J, Walker EA, Wylie-Rosett J, Orchard T, Kriska 
A, Jeffries S, Kramer MK, Smith M, Benchoff C, Guimond S, Pettigrew J, 
Rubinstein D, Semler L, Venditti E, Weinzierl V, Arakaki RF, Baker-Ladao NK, 
Isonaga MK, Bermudez NE, Mau MK, Melish JS, Yamamoto RE, Knowler WC, Cooeyate N, 
Enote A, Hoskin MA, Natewa C, Percy CA, Acton KJ, Andre VL, Barber R, Begay S, 
Bucca BC, Cook S, Curtis J, Dodge C, Doughty MS, Kurland J, Glass J, Glass M, 
Hanson RL, Ingraham LE, Kobus KM, Krakoff J, Manus C, McCabe C, Michaels S, 
Morgan T, Nelson JA, Piromalli C, Roy RJ, Sangster S, Smart M, Tonemah DP, 
Williams R, Wilson C, Fowler S, Temprosa M, Larsen M, Brenneman T, Sherif H, 
Edelstein SL, Abebe S, Bamdad J, Barkalow M, Bethepu J, Bezabeh T, Butler N, 
Callaghan J, Carter CE, Christophi C, Dwyer GM, Foulkes M, Gao Y, Gooding R, 
Gottlieb A, Grover N, Hoffman H, Tjaden AH, Jablonski K, Katz R, Kolinjivadi P, 
Lachin JM, Ma Y, Pan Q, Reamer S, Sapozhnikova A, Venditti EM, Kriska AM, Semler 
L, Weinzierl V, Marcovina S, Strylewicz G, Albers J, Fradkin J, Garfield S, Lee 
C, Gregg E, Zhang P, Florez JC, Altshuler D, Billings LK, Chen L, Harden M, 
Hanson RL, Knowler WC, Pollin TI, Shuldiner AR, Jablonski K, Franks PW, Hivert 
MF.

Author information:
(1)Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
(2)Diabetes Unit, Massachusetts General Hospital, Boston, MA.
(3)Programs in Metabolism and Medical and Population Genetics, Eli and Edythe L. 
Broad Institute of MIT and Harvard, Cambridge, MA.
(4)Department of Medicine, Harvard Medical School, Boston, MA.
(5)Research Unit on Lipids and Atherosclerosis, CIBERDEM, Institut 
d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, Reus, 
Spain.
(6)The Biostatistics Center, Department of Epidemiology and Biostatistics, 
Milken Institute School of Public Health, The George Washington University, 
Rockville, MD.
(7)Division of Metabolism, Endocrinology and Nutrition, VA Puget Sound Health 
Care System and University of Washington, Seattle, WA.
(8)Genomics Platform, Eli and Edythe L. Broad Institute of MIT and Harvard, 
Cambridge, MA.
(9)Department of Family Medicine and Public Health, University of California, 
San Diego, La Jolla, CA.
(10)Division of Cardiovascular Diseases, Department of Medicine, The University 
of Tennessee Health Science Center, Memphis, TN.
(11)Genetic & Molecular Epidemiology Unit, Lund University Diabetes Centre, 
Malmo, Sweden.
(12)Department of Public Health and Clinical Medicine, Umeå University, Umeå, 
Sweden.
(13)Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, 
MA.
(14)Diabetes Epidemiology and Clinical Research Section, National Institute of 
Diabetes and Digestive and Kidney Diseases, Phoenix, AZ.

Coronary artery disease (CAD) is more frequent among individuals with 
dysglycemia. Preventive interventions for diabetes can improve cardiometabolic 
risk factors (CRFs), but it is unclear whether the benefits on CRFs are similar 
for individuals at different genetic risk for CAD. We built a 201-variant 
polygenic risk score (PRS) for CAD and tested for interaction with diabetes 
prevention strategies on 1-year changes in CRFs in 2,658 Diabetes Prevention 
Program (DPP) participants. We also examined whether separate lifestyle 
behaviors interact with PRS and affect changes in CRFs in each intervention 
group. Participants in both the lifestyle and metformin interventions had 
greater improvement in the majority of recognized CRFs compared with placebo (P 
< 0.001) irrespective of CAD genetic risk (P interaction > 0.05). We detected 
nominal significant interactions between PRS and dietary quality and physical 
activity on 1-year change in BMI, fasting glucose, triglycerides, and HDL 
cholesterol in individuals randomized to metformin or placebo, but none of them 
achieved the multiple-testing correction for significance. This study confirms 
that diabetes preventive interventions improve CRFs regardless of CAD genetic 
risk and delivers hypothesis-generating data on the varying benefit of 
increasing physical activity and improving diet on intermediate cardiovascular 
risk factors depending on individual CAD genetic risk profile.

© 2019 by the American Diabetes Association.

DOI: 10.2337/db19-0097
PMCID: PMC6925585
PMID: 31636172 [Indexed for MEDLINE]
